
## Agnieszka Girstun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/774325/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differences in electrochemical response of prospective anticancer drugs IPBD and Cl-IPBD, doxorubicin and Vitamin C at plasmid modified glassy carbon. Bioelectrochemistry, 2021, 137, 107682.	4.6	3
2	Effect of Varying Expression of EpCAM on the Efficiency of CTCs Detection by SERS-Based Immunomagnetic Optofluidic Device. Cancers, 2020, 12, 3315.	3.7	13
3	Detection of Circulating Tumor Cells Using Membrane-Based SERS Platform: A New Diagnostic Approach for â€ <sup>-</sup> Liquid Biopsy'. Nanomaterials, 2019, 9, 366.	4.1	38
4	Effects of SRSF1 on subnuclear localization of topoisomerase I. Journal of Cellular Biochemistry, 2019, 120, 11794-11808.	2.6	5
5	Subnuclear Localization of Human Topoisomerase I. Journal of Cellular Biochemistry, 2017, 118, 407-419.	2.6	7
6	Phase Transition Detection in Accumulation of a Potential Anticancer Drug Cl-IPBD with DNA: Supercoiled and Linear pUC19 Plasmids. Electrochimica Acta, 2016, 210, 422-434.	5.2	5
7	Synergy of BID with doxorubicin in the killing of cancer cells. Oncology Reports, 2015, 33, 2143-50.	2.6	17
8	Proinsulin C-peptide potentiates the inhibitory action of insulin on glucose synthesis in primary cultured rabbit kidney-cortex tubules: Metabolic studies. Biochemistry and Cell Biology, 2014, 92, 1-8.	2.0	11
9	Nucleolar Protein Anchoring and Translocation. , 2013, , 209-247.		1
10	Trimeric purine nucleoside phosphorylase: Exploring postulated one-third-of-the-sites binding in the transition state. Bioorganic and Medicinal Chemistry, 2012, 20, 6758-6769.	3.0	12
11	Activities of Topoisomerase I in Its Complex with SRSF1. Biochemistry, 2012, 51, 1803-1816.	2.5	7
12	1.45Ã resolution crystal structure of recombinant PNP in complex with a pM multisubstrate analogue inhibitor bearing one feature of the postulated transition state. Biochemical and Biophysical Research Communications, 2010, 391, 703-708.	2.1	8
13	Overexpressed proteins may act as mops removing their ligands from the host cells: A case study of calf PNP. Biochemical and Biophysical Research Communications, 2010, 391, 1203-1209.	2.1	8
14	Overexpression, purification and characterization of functional calf purine nucleoside phosphorylase (PNP). Protein Expression and Purification, 2008, 61, 122-130.	1.3	12
15	Fragment responsible for translocation in the N-terminal domain of human topoisomerase I. Biochemical and Biophysical Research Communications, 2008, 366, 250-257.	2.1	6
16	Poly(ADP-ribose) Binds to the Splicing Factor ASF/SF2 and Regulates Its Phosphorylation by DNA Topoisomerase I. Journal of Biological Chemistry, 2008, 283, 19991-19998.	3.4	69
17	Thermodynamic studies of interactions of calf spleen PNP with acyclic phosphonate inhibitors. Nucleic Acids Symposium Series, 2008, 52, 663-664.	0.3	5
18	Cloning, Expression, Purification, and Some Properties of Calf Purine Nucleoside Phosphorylase. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 855-859.	1.1	3

#	Article	IF	CITATIONS
19	RRM Proteins Interacting with the Cap Region of Topoisomerase I. Journal of Molecular Biology, 2007, 369, 1098-1112.	4.2	15
20	Proteomic analysis of complexes formed by human topoisomerase I. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1749, 133-141.	2.3	49
21	SF2/ASF protein binds to the cap region of human topoisomerase I through two RRM domains. Biochemical and Biophysical Research Communications, 2005, 331, 398-403.	2.1	18
22	Activation of human topoisomerase I by protein kinase CK2. Molecular Biology Reports, 2003, 30, 107-111.	2.3	10
23	SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase l. FEBS Journal, 2002, 269, 3504-3510.	0.2	16
24	Potential protein partners for the N-terminal domain of human topoisomerase I revealed by phage display. Molecular Biology Reports, 2002, 29, 347-352.	2.3	7